Front line treatment of chronic graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 124-133

  Martin, Paul J ^a   Gilman, Andrew L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054743948     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.013     Document Type: Chapter

References (35)

1. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versushost disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–276.
2. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus- host syndrome in man: a long-term clinicopathologic studyof 20 Seattle patients. Am J Med. 1980;69:204–217.
3. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood and Marrow Transplantation. 2003;9:215–233.
4. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97:1196–1201.
5. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11:945–956.
6. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft- versus- host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000;32:1265–1271.
7. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546–554.
8. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428–1435.
9. Akpek G, Zahurak ML, Piantadosi S, et al. Development of aprognostic modes for grading chronic graft-versus-host disease. Blood. 2001;97:1219–1226.
10. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104:3501–3506.
11. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versushost disease: association with treatment-related mortality and relapse. Blood. 2002;100:406–414.
12. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versushost disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9:38–45.
13. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604–3609.
14. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96:3995–3996.
15. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graftversus- host disease. Biol Blood Marrow Transplant. 2001;7: 265–273.
16. Koc S, Leisenring W, Flowers MED, et al. Therapy for chronic graftversus- host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–53.
17. Cooper MS, Stewart PM. Current concepts: corticosteroid insufficiency in acutely ill patients. New Engl J Med. 2003;348:727–734.
18. Axelrod L. Glucocorticoid therapy. Medicine. 1976;55:39–65.
19. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood. 1988;72:555–561.
20. Flowers, MED, Lee S, Vogelsang G. An update on how to treat chronic GVHD (letter). Blood. 2003;102:2312.
21. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant. 2000;25:1067–1071.
22. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:307–313.
23. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6;327–334.
24. Gaziev D, Lucarelli G, Polchi P, et al. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. Bone Marrow Transplant. 2001;27:45–51.
25. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996;17;1061–1067.
26. Schultz KR, Green GJ, Wensley D, et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood. 1994;84:3212–3220.
27. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657–666.
28. Couriel, D, Carpenter, P, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant. 2006;12:375–396.
29. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.Blood. 2003;101:831–836.
30. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–414.
31. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive Aspergillosis in allogeneic stem cell transplant recipients:changes in epidemiology and risk factors. Blood. 2002;100: 4358–4366.
32. Ullman AJ, Lipton JH, Vasole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. New Engl J Med. 2007;356:335–347.
33. Kikuchi T, Parker P, Wu M, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Bone Marrow Transplant. 2006;13:1016–1021.
34. Flowers, MED. Traditional treatment of chronic graft-versushost disease. Blood and Marrow Transplantation Reviews. 2002;12:5–8.
35. Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long term follow up of a randomized trial. Blood. 2002;100:48–51.